Trump says he’ll ‘always fight’ for people with pre-existing conditions; DOJ’s stance says otherwise

As the U.S. Department of Justice works to help nullify the Affordable Care Act, recent comments by President Donald Trump directly contradict his administration’s stance.

According to a report by the Association Press, Trump stated he would “always fight” for people with pre-existing conditions during a rally in West Virginia over the weekend. One component of the ACA is it requires insurers to take all applicants, regardless of medical history, and patients with health problems pay the same standard premiums as healthy individuals.

"I will always fight for and always protect patients with pre-existing conditions. ... We'll do it the right way, too. Pre-existing conditions are safe, OK? Just remember that,” Trump said.

The president’s statement differs from the DOJ’s stance in a lawsuit that’s seeking to make the healthcare law unconstitutional.

“Government attorneys told a court in June that they will no longer defend key parts of Obamacare, including provisions that guarantee access to health insurance regardless of any medical conditions,” the report said.

“The Trump administration said it won't defend the individual mandate or provisions shielding people with medical conditions from being denied coverage or charged higher premiums. But it said the rest of the law, including Medicaid expansion, can remain.”

To read the full report, click the link below.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.